HUTCHMED (China) (HKG:0013) and Innovent Biologics (HKG:1801) said their FRUSICA-2 Phase II/III study of fruquintinib in combination with sintilimab as a second line of treatment for advanced renal cell carcinoma in China met its primary endpoint of progression-free survival (PFS).
Іn addition to the primary endpoint, the combination therapy also demonstrated improvements in secondary endpoints including objective response rate and duration of response.
Complete results will be presented at an upcoming conference, according to a Wednesday filing with the Hong Kong bourse.
The combo therapy also secured conditional approval for treating advanced endometrial cancer from China's National Medical Products Association.
Hutchmed's shares were up by 4%, while those of Innovent were down 1% in recent trade.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。